Delayed Denial: Cornerstone’s Lixivaptan Gets FDA “Complete Response”
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency’s action letter on the hyponatremia drug was delayed for two days due to the closure of federal government offices in the midst of Hurricane Sandy. Cornerstone said the agency has requested additional clinical and non-clinical data.